이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Patient Convenience Study

2018년 10월 8일 업데이트: Boehringer Ingelheim

Non-interventional Study Describing Patients' Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamin K Antagonist for Stroke Prophylaxis in Atrial Fibrillation

The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa® to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its approved indication in the approved dosages of 110 mg or 150 mg twice daily) in comparison to standard care using Vitamin K Antagonist (VKA).

연구 개요

상태

완전한

정황

연구 유형

관찰

등록 (실제)

1852

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 그리스
      • Agrinio, 그리스
        • 1160.247.3410 Boehringer Ingelheim Investigational Site
      • Alexandroupoli, 그리스
        • 1160.247.3306 Boehringer Ingelheim Investigational Site
      • Arta, 그리스
        • 1160.247.3411 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3100 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3101 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3102 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3103 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3104 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3105 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3106 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3107 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3108 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3109 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3110 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3111 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3113 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3114 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3116 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3118 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3119 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3120 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3121 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3122 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3200 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3202 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3203 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3204 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3206 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3207 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3208 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3211 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3212 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3213 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3214 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3217 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.247.3218 Boehringer Ingelheim Investigational Site
      • Chalkidiki, 그리스
        • 1160.247.3316 Boehringer Ingelheim Investigational Site
      • Chania, 그리스
        • 1160.247.3219 Boehringer Ingelheim Investigational Site
      • Drama, 그리스
        • 1160.247.3315 Boehringer Ingelheim Investigational Site
      • Giannitsa, 그리스
        • 1160.247.3307 Boehringer Ingelheim Investigational Site
      • Glyfada, Athens, 그리스
        • 1160.247.3216 Boehringer Ingelheim Investigational Site
      • Hrakleion ,Crete, 그리스
        • 1160.247.3215 Boehringer Ingelheim Investigational Site
      • Ierapetra, Crete, 그리스
        • 1160.247.3201 Boehringer Ingelheim Investigational Site
      • Ioannina, 그리스
        • 1160.247.3400 Boehringer Ingelheim Investigational Site
      • Ioannina, 그리스
        • 1160.247.3408 Boehringer Ingelheim Investigational Site
      • Ioannina, 그리스
        • 1160.247.3409 Boehringer Ingelheim Investigational Site
      • Kalamata, 그리스
        • 1160.247.3402 Boehringer Ingelheim Investigational Site
      • Karditsa, 그리스
        • 1160.247.3407 Boehringer Ingelheim Investigational Site
      • Katerini, 그리스
        • 1160.247.3318 Boehringer Ingelheim Investigational Site
      • Kavala, 그리스
        • 1160.247.3312 Boehringer Ingelheim Investigational Site
      • Kerkyra, 그리스
        • 1160.247.3404 Boehringer Ingelheim Investigational Site
      • Komotini, 그리스
        • 1160.247.3320 V.Pavlou 21 , Komotini
      • Larissa, 그리스
        • 1160.247.3415 Boehringer Ingelheim Investigational Site
      • Patra, 그리스
        • 1160.247.3412 Boehringer Ingelheim Investigational Site
      • Patra, 그리스
        • 1160.247.3416 Boehringer Ingelheim Investigational Site
      • Serres, 그리스
        • 1160.247.3317 Boehringer Ingelheim Investigational Site
      • Thessaloniki, 그리스
        • 1160.247.3300 Boehringer Ingelheim Investigational Site
      • Thessaloniki, 그리스
        • 1160.247.3301 Boehringer Ingelheim Investigational Site
      • Thessaloniki, 그리스
        • 1160.247.3303 Boehringer Ingelheim Investigational Site
      • Thessaloniki, 그리스
        • 1160.247.3304 Boehringer Ingelheim Investigational Site
      • Thessaloniki, 그리스
        • 1160.247.3305 Boehringer Ingelheim Investigational Site
      • Thessaloniki, 그리스
        • 1160.247.3308 Boehringer Ingelheim Investigational Site
      • Thessaloniki, 그리스
        • 1160.247.3309 Boehringer Ingelheim Investigational Site
      • Thessaloniki, 그리스
        • 1160.247.3313 Boehringer Ingelheim Investigational Site
      • Thessaloniki, 그리스
        • 1160.247.3314 Boehringer Ingelheim Investigational Site
      • Thessaloniki, 그리스
        • 1160.247.3319 Boehringer Ingelheim Investigational Site
      • Trikala, 그리스
        • 1160.247.3406 Boehringer Ingelheim Investigational Site
      • Tripoli, 그리스
        • 1160.247.3403 Boehringer Ingelheim Investigational Site
      • Veroia, 그리스
        • 1160.247.3310 Boehringer Ingelheim Investigational Site
      • Volos, 그리스
        • 1160.247.3401 Boehringer Ingelheim Investigational Site
      • Xanthi, 그리스
        • 1160.247.3405 Boehringer Ingelheim Investigational Site
      • Xilokastro, 그리스
        • 1160.247.3413 Boehringer Ingelheim Investigational Site
  • 네덜란드
      • Amsterdam, 네덜란드
        • 1160.247.4004 Boehringer Ingelheim Investigational Site
      • Beugen, 네덜란드
        • 1160.247.4010 Boehringer Ingelheim Investigational Site
      • Capelle A/d Ijssel, 네덜란드
        • 1160.247.4013 Boehringer Ingelheim Investigational Site
      • Den Haag, 네덜란드
        • 1160.247.4002 Boehringer Ingelheim Investigational Site
      • EDE, 네덜란드
        • 1160.247.4006 Boehringer Ingelheim Investigational Site
      • Goes, 네덜란드
        • 1160.247.4009 Boehringer Ingelheim Investigational Site
      • Groningen, 네덜란드
        • 1160.247.4001 Boehringer Ingelheim Investigational Site
      • Heerenveen, 네덜란드
        • 1160.247.4008 Boehringer Ingelheim Investigational Site
      • Heerlen, 네덜란드
        • 1160.247.4012 Boehringer Ingelheim Investigational Site
      • Nijmegen, 네덜란드
        • 1160.247.4005 Boehringer Ingelheim Investigational Site
      • Schiedam, 네덜란드
        • 1160.247.4011 Boehringer Ingelheim Investigational Site
      • Uden, 네덜란드
        • 1160.247.4007 Boehringer Ingelheim Investigational Site
      • Veldhoven, 네덜란드
        • 1160.247.4003 Boehringer Ingelheim Investigational Site
  • 노르웨이
      • Bergen, 노르웨이
        • 1160.247.5001 Boehringer Ingelheim Investigational Site
      • Førde, 노르웨이
        • 1160.247.5007 Boehringer Ingelheim Investigational Site
      • Lierskogen, 노르웨이
        • 1160.247.5008 Boehringer Ingelheim Investigational Site
      • Nesbru, 노르웨이
        • 1160.247.5009 Boehringer Ingelheim Investigational Site
      • Oslo, 노르웨이
        • 1160.247.5004 Boehringer Ingelheim Investigational Site
      • Oslo, 노르웨이
        • 1160.247.5005 Boehringer Ingelheim Investigational Site
      • Stavanger, 노르웨이
        • 1160.247.5010 Boehringer Ingelheim Investigational Site
      • Svelvik, 노르웨이
        • 1160.247.5006 Boehringer Ingelheim Investigational Site
  • 덴마크
      • Frederikssund, 덴마크
        • 1160.247.2006 Boehringer Ingelheim Investigational Site
      • Herning, 덴마크
        • 1160.247.2008 Boehringer Ingelheim Investigational Site
      • Hjørring, 덴마크
        • 1160.247.2001 Sygehus Vendsyssel
      • Hvidovre, 덴마크
        • 1160.247.2007 Hvidovre Hospital
      • Nykøbing F, 덴마크
        • 1160.247.2005 Boehringer Ingelheim Investigational Site
      • Næstved, 덴마크
        • 1160.247.2003 Boehringer Ingelheim Investigational Site
      • Roskilde, 덴마크
        • 1160.247.2009 Boehringer Ingelheim Investigational Site
      • Svendborg, 덴마크
        • 1160.247.2004 Boehringer Ingelheim Investigational Site
  • 벨기에
      • Braine-l'Alleud, 벨기에
        • 1160.247.1019 Boehringer Ingelheim Investigational Site
      • Brussel, 벨기에
        • 1160.247.1018 Boehringer Ingelheim Investigational Site
      • Brussels, 벨기에
        • 1160.247.1020 Boehringer Ingelheim Investigational Site
      • Bruxelles, 벨기에
        • 1160.247.1001 Boehringer Ingelheim Investigational Site
      • De Pinte, 벨기에
        • 1160.247.1013 Boehringer Ingelheim Investigational Site
      • Dendermonde, 벨기에
        • 1160.247.1010 Boehringer Ingelheim Investigational Site
      • Diest, 벨기에
        • 1160.247.1011 Boehringer Ingelheim Investigational Site
      • Edegem, 벨기에
        • 1160.247.1014 Boehringer Ingelheim Investigational Site
      • Leuven, 벨기에
        • 1160.247.1007 Boehringer Ingelheim Investigational Site
      • Lier, 벨기에
        • 1160.247.1021 Boehringer Ingelheim Investigational Site
      • Maaseik, 벨기에
        • 1160.247.1002 Boehringer Ingelheim Investigational Site
      • Meise, 벨기에
        • 1160.247.1015 Boehringer Ingelheim Investigational Site
      • Mol, 벨기에
        • 1160.247.1008 Boehringer Ingelheim Investigational Site
      • Mol, 벨기에
        • 1160.247.1016 Boehringer Ingelheim Investigational Site
      • Mons, 벨기에
        • 1160.247.1005 Boehringer Ingelheim Investigational Site
      • Nijlen, 벨기에
        • 1160.247.1009 Boehringer Ingelheim Investigational Site
      • Ottignies - Louvain-la-neuve, 벨기에
        • 1160.247.1003 Boehringer Ingelheim Investigational Site
      • Roeselare, 벨기에
        • 1160.247.1012 Boehringer Ingelheim Investigational Site
      • Tienen, 벨기에
        • 1160.247.1017 Boehringer Ingelheim Investigational Site
  • 스웨덴
      • Bandhagen, 스웨덴
        • 1160.247.7016 Boehringer Ingelheim Investigational Site
      • Broby, 스웨덴
        • 1160.247.7013 Boehringer Ingelheim Investigational Site
      • Göteborg, 스웨덴
        • 1160.247.7006 Boehringer Ingelheim Investigational Site
      • Göteborg, 스웨덴
        • 1160.247.7007 Boehringer Ingelheim Investigational Site
      • Göteborg, 스웨덴
        • 1160.247.7014 Boehringer Ingelheim Investigational Site
      • Hässleholm, 스웨덴
        • 1160.247.7011 Boehringer Ingelheim Investigational Site
      • Kristianstad, 스웨덴
        • 1160.247.7019 Boehringer Ingelheim Investigational Site
      • Malmö, 스웨덴
        • 1160.247.7005 Boehringer Ingelheim Investigational Site
      • Stockholm, 스웨덴
        • 1160.247.7001 Boehringer Ingelheim Investigational Site
      • Stockholm, 스웨덴
        • 1160.247.7002 Boehringer Ingelheim Investigational Site
      • Stockholm, 스웨덴
        • 1160.247.7003 Boehringer Ingelheim Investigational Site
      • Stockholm, 스웨덴
        • 1160.247.7004 Boehringer Ingelheim Investigational Site
      • Stockholm, 스웨덴
        • 1160.247.7008 Boehringer Ingelheim Investigational Site
      • Stockholm, 스웨덴
        • 1160.247.7010 Boehringer Ingelheim Investigational Site
      • Stockholm, 스웨덴
        • 1160.247.7012 Boehringer Ingelheim Investigational Site
      • Stockholm, 스웨덴
        • 1160.247.7017 Boehringer Ingelheim Investigational Site
      • Värnamo, 스웨덴
        • 1160.247.7009 Boehringer Ingelheim Investigational Site
      • Västerås, 스웨덴
        • 1160.247.7015 Boehringer Ingelheim Investigational Site
  • 포르투갈
      • Amadora, 포르투갈
        • 1160.247.6003 Boehringer Ingelheim Investigational Site
      • Angra do Heroísmo, 포르투갈
        • 1160.247.6012 Boehringer Ingelheim Investigational Site
      • Aveiro, 포르투갈
        • 1160.247.6007 Boehringer Ingelheim Investigational Site
      • Braga, 포르투갈
        • 1160.247.6004 Boehringer Ingelheim Investigational Site
      • Guimarães, 포르투갈
        • 1160.247.6006 Boehringer Ingelheim Investigational Site
      • Horta, 포르투갈
        • 1160.247.6013 Boehringer Ingelheim Investigational Site
      • Matosinhos, 포르투갈
        • 1160.247.6002 Boehringer Ingelheim Investigational Site
      • Penafiel, 포르투갈
        • 1160.247.6009 Boehringer Ingelheim Investigational Site
      • Viana do Castelo, 포르투갈
        • 1160.247.6008 Boehringer Ingelheim Investigational Site
      • Vila Franca de Xira, 포르투갈
        • 1160.247.6005 Boehringer Ingelheim Investigational Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

European patients with non valvular atrial fibrillation

설명

Inclusion criteria:

Cohort A:

  1. A. Written informed consent prior to participation
  2. A. Female and male patients >= 18 years of age with a diagnosis of non-valvular atrial fibrillation.
  3. A. At least 3 months of continuous VKA treatment for stroke prevention prior to baseline assessment.
  4. A. Patients switched to Pradaxa® according Summary of Product Characteristics and physician's discretion.

OR

Cohort B:

  1. B. Written informed consent prior to participation.
  2. B. Female and male patients >= 18 years of age newly diagnosed with non-valvular atrial fibrillation and no previous treatment for stroke prevention (no use of any oral anticoagulant (OAC) within one year prior to enrolment).
  3. B. Stroke prevention treatment initiated with Pradaxa® or VKA according to Summary of Product Characteristics and physician's discretion.

Exclusion criteria:

  1. Contraindication to the use of Pradaxa® or VKA as described in the Summary of Product Characteristics (SmPC).
  2. Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in atrial fibrillation.
  3. Current participation in any clinical trial of a drug or device.
  4. Current participation in an European registry on the use of oral anticoagulation in AF.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: 보병대
  • 시간 관점: 유망한

코호트 및 개입

그룹/코호트
Switch patients / A
Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
New AF patients / B
Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Mean Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second and Last Assessment Compared to Baseline Assessment
기간: Baseline, Visit 2 (7-124 days after initiation on Pradaxa® or VKA), Visit 3 (125-365 days after initiation on Pradaxa® or VKA).
The PACT-Q is a self-administered questionnaire which was developed as a means to investigate patients´ satisfaction with anticoagulant treatment and treatment convenience in patients with deep venous thrombosis (DVT), pulmonary embolism (PE) or atrial fibrillation (AF). The PACT-Q2 is composed of three dimensions covering: convenience (11 items), burden of disease and treatment (2 items), and anticoagulant treatment satisfaction (7 items). Items for convenience and for burden of disease and treatment were reversed (reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score (CDS). Items for anticoagulant treatment satisfaction are summed and rescaled on a 0-100 scale to determine the satisfaction dimension score (SDS). High scores are more favorable. The two dimension scores are presented for Baseline, Visit 2 (second assessment) and Visit 3 (last assessment) as mean and standard deviation (SD).
Baseline, Visit 2 (7-124 days after initiation on Pradaxa® or VKA), Visit 3 (125-365 days after initiation on Pradaxa® or VKA).
Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups
기간: Visit 2 (7-124 days after initiation on Pradaxa® or VKA) and Visit 3 (125-365 days after initiation on Pradaxa® or VKA).
The PACT-Q2 is composed of three dimensions covering: convenience (11 items), burden of disease and treatment (2 items), and anticoagulant treatment satisfaction (7 items). The PACT-Q2 was to be administered to patients once treatment was ongoing. Items for convenience and for burden of disease and treatment were reversed (reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score. Items for anticoagulant treatment satisfaction are summed and rescaled on a 0-100 scale to determine the satisfaction dimension score. High scores are more favorable. The two dimension scores are presented for Visit 2 (second assessment) and Visit 3 (last assessment) as mean and standard deviation (SD). Propensity score matching method is used to identify matched Pradaxa® and VKA patients. Only the matched patients in each treatment group are summarized and used for comparison.
Visit 2 (7-124 days after initiation on Pradaxa® or VKA) and Visit 3 (125-365 days after initiation on Pradaxa® or VKA).
Patient Characterization at Baseline - Categorical Parameters
기간: Baseline
Categorical parameters of the patient characteristics at baseline included age, gender, Stroke- and/or bleeding related risk factors in medical history and at baseline (MH), co-morbidities (CoMo), concomitant therapies (CM) and dosing of Pradaxa® (DoP).
Baseline
Patient Characteristics at Baseline - CHA2DS2-VASc Stroke Risk Score and HAS-BLED Bleeding Risk Score
기간: Baseline
CHA2DS2-VASc stroke risk score is calculated based on the following conditions: Congestive heart failure, Hypertension, Age (≥ 75), Diabetes Mellitus, Stroke/ Transient Ischaemic Attack (TIA), Vascular disease, Age 65-74, Sex category. HAS-BLED bleeding risk score is calculated based on the following conditions: Hypertension, Abnormal renal and Hypertension, Abnormal renal and liver function, Stroke (1 point), Bleeding history or predisposition, Labile INR, Elderly (>65 years), Drugs and Alcohol. CHA2DS2-VASc stroke risk score may range from 0 to 9 with 0 being the best outcome. HAS-BLED bleeding risk score may range from 0 to 9 with 0 being the best outcome. CHA2DS2-VASc stroke risk score and HAS-BLED bleeding risk score at baseline are patient characteristics.
Baseline
Patient Characterization at Baseline - Creatinine Clearance
기간: Baseline
Creatinine clearance at baseline is a measure of the patient's kidney function and is one of the baseline patient characteristics.
Baseline
Patient Characteristics at Baseline - Vitamin K Antagonist Treatment Duration
기간: Baseline
Vitamin K Antagonist (VKA) treatment duration at baseline is only applicable for Cohort A patients and is one of the baseline patient characteristics.
Baseline

2차 결과 측정

결과 측정
측정값 설명
기간
Mean PACT-Q2 Scores, for Patients in Cohort A, at Last Assessment Compared to Second Assessment
기간: Visit 2 (7-124 days after initiation on Pradaxa® or VKA) and Visit 3 (125-365 days after initiation on Pradaxa® or VKA).
The PACT-Q2 is composed of three dimensions covering: convenience (11 items), burden of disease and treatment (2 items), and anticoagulant treatment satisfaction (7 items). The PACT-Q2 was to be administered to patients once treatment was ongoing. Items for convenience and for burden of disease and treatment were reversed (reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score. Items for anticoagulant treatment satisfaction are summed and rescaled on a 0-100 scale to determine the satisfaction dimension score. High scores are more favorable. The two dimension scores are presented for Visit 2 (second assessment) and Visit 3 (last assessment) as mean and standard deviation (SD).
Visit 2 (7-124 days after initiation on Pradaxa® or VKA) and Visit 3 (125-365 days after initiation on Pradaxa® or VKA).
Description of PACT-Q1 Items for Patients in Cohort B at Baseline
기간: Baseline
The PACT-Q1 is composed of a single dimension (7 items), covering the expectations of patients regarding their anticoagulant treatment, and was to be administered before treatment initiation. The 7 items are: A1: How confident are you that your anticoagulant treatment will prevent blood clots? A2: Do you expect that your anticoagulant treatment will relieve some of the symptoms you experience? A3: Do you expect that your anticoagulant treatment will cause side effects such as minor bruises or bleeding? A4: How important is it for you to have an anticoagulant treatment that is easy to take? A5: How concerned are you about making mistakes when taking your anticoagulant treatment? A6: How important is it for you to take care of your anticoagulant treatment by yourself? A7: How concerned are you about how much you pay for your anticoagulant treatment? Responses ranged from 1 (Not at all) to 5 (Extremely/ Completely/ Very much).
Baseline

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Boehringer Ingelheim

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2015년 11월 11일

기본 완료 (실제)

2017년 1월 30일

연구 완료 (실제)

2017년 1월 30일

연구 등록 날짜

최초 제출

2015년 11월 4일

QC 기준을 충족하는 최초 제출

2015년 11월 4일

처음 게시됨 (추정)

2015년 11월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2019년 2월 21일

QC 기준을 충족하는 마지막 업데이트 제출

2018년 10월 8일

마지막으로 확인됨

2018년 10월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • 1160.247

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다